Spots Global Cancer Trial Database for Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
Official Title: Phase I Dose Finding Study of the Orally Bioavailable Platinum Analog Satraplatin in Combination With Abraxane (Paclitaxel Protein-bound Particles) in Advanced Cancers
Study ID: NCT00473720
Conditions
Study Description
Brief Summary: This is a phase I dose escalating study of oral satraplatin in combination with Abraxane administered weekly for three out of every four weeks in patients with advanced solid cancers.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Yale University, Comprehensive Cancer Center, New Haven, Connecticut, United States
Contact Details
Name: Hari Deshpande, M.D.
Affiliation: Yale University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
